DYN stock forecast, quote, news & analysis
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases... Show more
Why Dyne Therapeutics (DYN) Stock Is Down 37% in the Last 30 Days
Key Takeaways
- Dyne Therapeutics (DYN) shares fell roughly 37% over the last 30 days, declining from about $26.34 to $16.51.
- The sharp selloff was triggered by Novartis (NVS) reporting a Phase 3 failure for del-desiran in myotonic dystrophy type 1 (DM1), rattling the broader muscle-disease drug sector.
- Wall Street responded with a wave of price-target cuts, though most analysts retained bullish ratings; JPMorgan moved to an Underweight stance.
- The decline follows a strong earlier 2026 rally that took DYN to a 52-week high near $27.30 in August.
- Company-specific milestones, including the FDA's Priority Review of z-rostudirsen for Duchenne muscular dystrophy, remain on track.
Dyne Therapeutics (DYN) Company Overview and Market Position
Dyne Therapeutics is a clinical-stage biotechnology company focused on genetically driven neuromuscular diseases. Its proprietary FORCE platform uses an antibody fragment (Fab), linker, and oligonucleotide payload to deliver therapeutics to muscle tissue and the central nervous system. The company's two lead programs are z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping, and z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1). Dyne is also advancing preclinical candidates for additional DMD exons, facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease. Investors follow the stock closely because of its broad rare-disease pipeline and the absence of approved treatments for several of these conditions.
Dyne Therapeutics (DYN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DYN shares dropped approximately 37%, from a closing price near $26.34 to about $16.51. Most of that decline occurred in a single week, when the stock gapped lower and then continued to slide as analysts reassessed the risk profile of the company's DM1 program.
The quarterly picture is more nuanced. Around 90 days ago, DYN traded near $20.94, meaning the stock is down roughly 21% over the trailing three months despite the sharp August peak. During the quarter, shares first climbed steadily on positive DMD data and regulatory momentum, reaching a 52-week high near $27.30 in mid-August, before the September sector-wide shock erased those gains and pushed the stock well below its late-June level.
What Drove DYN Stock Price in the Last 30 Days
The primary catalyst was external rather than company-specific. On September 8, 2026, Novartis reported that its Phase 3 study of del-desiran — a DM1 treatment acquired through its roughly $12 billion purchase of Avidity — failed to meet its primary endpoint based on video hand opening time (vHOT). Because Dyne's z-basivarsen targets the same disease and also uses vHOT as a key measure, investors reassessed the probability of success across the entire DM1 category. DYN fell nearly 18% in a single session and continued to weaken in subsequent days.
The read-through prompted broad analyst revisions. Baird cut its price target to $26 from $30, RBC Capital to $30 from $35, and Morgan Stanley to $36 from $45, with all three maintaining positive ratings. JPMorgan was more bearish, downgrading the stock to Underweight with a $10 target. Despite the slide, most of the sell-side retained a bullish view, noting differences in drug design and trial structure between Dyne's and Novartis' programs.
What Drove DYN Stock Performance Over the Last Quarter
The quarterly trend was shaped by two opposing forces. On the positive side, Dyne delivered a steady stream of encouraging updates: the FDA accepted a Biologics License Application for z-rostudirsen with Priority Review and a PDUFA target action date of January 21, 2027, while new cardiopulmonary data from the DELIVER trial reinforced the potential of the FORCE platform. The company also reported a cash position of roughly $972 million as of March 31, 2026, supporting operations into 2028.
Those developments carried the stock to a 52-week high in August. The September Novartis failure then reversed that momentum, as concerns about the DM1 mechanism and endpoint reliability outweighed the company's DMD progress. The result was a net quarterly decline of roughly 21% despite a strong intra-quarter rally.
Trending AI Robots
For traders seeking a systematic approach to market volatility, Tickeron's Trending AI Robots page offers a curated view of the platform's top-performing automated strategies. Tickeron hosts hundreds of AI trading bots that trade thousands of tickers, but only the most relevant and best-performing bots are featured in this section. Each bot varies in strategy, timeframe, and performance metrics, allowing users to explore approaches that range from short-term momentum to longer-horizon positioning. The section is designed to help investors identify currently favored strategies without manual screening. Explore the Trending AI Robots page to review the bots currently generating the strongest signals.
DYN Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching several catalysts that could determine DYN's trajectory. The PDUFA target action date of January 21, 2027 for z-rostudirsen is a central event, with a potential U.S. launch in the first quarter of 2027 if approval is granted. Topline data from the ACHIEVE registrational expansion cohort of z-basivarsen in DM1 is expected in the first quarter of 2027, with a potential BLA submission in early Q3 2027 — a readout made more significant by the Novartis setback. Nearer term, the company plans to present additional one-year ACHIEVE data at the World Muscle Society and AANEM meetings, which could help clarify functional outcomes and safety durability. Macroeconomic conditions, biotech financing sentiment, and competitive developments in the DM1 and DMD spaces remain important external factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DYN in +0.18% Uptrend, advancing for three consecutive days on September 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DYN advanced for three days, in 240 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for DYN just turned positive on October 01, 2026. Looking at past instances where DYN's MACD turned positive, the stock continued to rise in 34 of 43 cases over the following month. The odds of a continued upward trend are 79%.
DYN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DYN as a result. In 67 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
DYN moved below its 50-day moving average on September 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DYN crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for DYN entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.346) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. DYN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology